GSK-3 Inhibitor II (CAS 478482-75-6)
See product citations (11)
QUICK LINKS
GSK-3 Inhibitor II is primarily utilized in research focused on its role in modulating the glycogen synthase kinase 3 (GSK-3) pathway, which is critical for numerous cellular functions including metabolism, cell division, and gene expression. This compound is particularly valuable in studies aimed at understanding the molecular mechanisms of neurodevelopmental and neurodegenerative disorders, as GSK-3 is implicated in processes such as neuronal cell development and synaptic plasticity. Research involving GSK-3 Inhibitor II often explores its potential to alter cell signaling pathways that contribute to disease progression in certain conditions. Additionally, it is used in investigations that examine the kinase′s role in regulating apoptosis and cellular responses to DNA damage. Furthermore, GSK-3 Inhibitor II aids in the study of glycogen metabolism, providing insights into how alterations in kinase activity can affect energy storage and utilization.
GSK-3 Inhibitor II (CAS 478482-75-6) References
- Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. | Naerum, L., et al. 2002. Bioorg Med Chem Lett. 12: 1525-8. PMID: 12031334
- A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. | Jing, H., et al. 2004. J Biol Chem. 279: 55176-86. PMID: 15498767
- Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. | Koh, SH., et al. 2005. Eur J Neurosci. 22: 301-9. PMID: 16045483
- KLHL1/MRP2 mediates neurite outgrowth in a glycogen synthase kinase 3beta-dependent manner. | Seng, S., et al. 2006. Mol Cell Biol. 26: 8371-84. PMID: 16982692
- Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. | Koh, SH., et al. 2007. Exp Neurol. 205: 336-46. PMID: 17433298
- Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions. | Koh, SH., et al. 2008. Biochem Biophys Res Commun. 371: 894-9. PMID: 18477469
- Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. | Gimenez-Cassina, A., et al. 2009. J Biol Chem. 284: 3001-3011. PMID: 19033437
- Valproate attenuates accelerated atherosclerosis in hyperglycemic apoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis. | Bowes, AJ., et al. 2009. Am J Pathol. 174: 330-42. PMID: 19095952
- GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. | Wada, A. 2009. Front Biosci (Landmark Ed). 14: 1558-70. PMID: 19273146
- Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. | Wang, Y., et al. 2009. Diabetes. 58: 1391-402. PMID: 19324938
- Myocardial stress remodelling after regional infarction is independent of glycogen synthase kinase-3 inactivation. | Webb, IG., et al. 2010. J Mol Cell Cardiol. 49: 897-900. PMID: 20696171
- Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells. | Ito, K., et al. 2013. Vet J. 196: 536-40. PMID: 23369384
- Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. | Lahmy, V., et al. 2013. Neuropsychopharmacology. 38: 1706-23. PMID: 23493042
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GSK-3 Inhibitor II, 5 mg | sc-24020 | 5 mg | $80.00 | |||
GSK-3 Inhibitor II, 25 mg | sc-24020A | 25 mg | $290.00 |